EUVIMEDEUVIMED entdecken
Crossref

Exploiting Acquired Drug Resistance in Pancreatic Cancer through Selective Covalent Targeting of MAP2K4/7

Gina M Connors, Thao D Pham, Jeffrey H Becker, Aria A Argus, Kenkichi Baba, Takayoshi Kinoshita, Hidayatullah G Munshi, Karl A Scheidt iD

ACS Chemical Biology · 2026

DOI: 10.1021/acschembio.6c00580 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Biology, 2026. Verfasst von Gina M Connors und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Northwestern University, Evanston, Illinois60208, United States. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, MAP Kinase Kinase 4. Die Arbeit nennt 47 Literaturangaben. Gefördert von: NCI NIH HHS, Osaka University, Northwestern University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is highly lethal and remains largely refractory to targeted therapy despite its near-universal dependence on oncogenic KRAS. Single-agent KRAS inhibitors often fail due to adaptive resistance mechanisms that emerge under pharmacologic pressure. Previous studies combining MAP2K4 inhibition with KRASG12C-targeted therapy determined that partial JNK suppression can enhance anticancer responses. Here, we extend this concept to PDAC, which is predominantly driven by KRASG12D mutations, and demonstrate that full JNK pathway inactivation restores sensitivity to KRAS inhibition in resistant cells. Using selective MAP2K4, MAP2K7, or combined inhibitors, we show that more extensive JNK suppression disables the feedback loop that reactivates KRAS signaling. In contrast, KRASG12D inhibitor-sensitive cells derive no benefit from JNK pathway inhibition, revealing a resistance-specific vulnerability amenable to therapeutic exploitation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmPancreatic NeoplasmsCarcinoma, Pancreatic DuctalMAP Kinase Kinase 4Protein Kinase InhibitorsAntineoplastic AgentsHumansProto-Oncogene Proteins p21(ras)Cell Line, Tumor

Substanzen

MAP Kinase Kinase 4Proto-Oncogene Proteins p21(ras)Protein Kinase InhibitorsMAP2K4 protein, humanAntineoplastic AgentsKRAS protein, human

Autor:innen und Institutionen

  • Department of Chemistry, Northwestern University, Evanston, Illinois60208, United States.
  • Department of Medicine, Feinberg School of Medicine, and The Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois60611, United States.
  • Graduate School of Science, Osaka Metropolitan University, Sakai, Osaka599-8531, Japan.

ORCID-Profile: Karl A Scheidt

Förderung

  • NCI NIH HHS
  • Osaka University
  • Northwestern University
  • National Cancer Institute

Zitieren

APA

Connors, G. M., Pham, T. D., Becker, J. H., Argus, A. A., Baba, K., Kinoshita, T., Munshi, H. G., & Scheidt, K. A. (2026). Exploiting Acquired Drug Resistance in Pancreatic Cancer through Selective Covalent Targeting of MAP2K4/7. ACS Chemical Biology. https://doi.org/10.1021/acschembio.6c00580

Vancouver

Connors GM, Pham TD, Becker JH, Argus AA, Baba K, Kinoshita T, et al. Exploiting Acquired Drug Resistance in Pancreatic Cancer through Selective Covalent Targeting of MAP2K4/7. ACS Chemical Biology. 2026. doi:10.1021/acschembio.6c00580

BibTeX
@article{Connors2026,
  author = {Connors, Gina M and Pham, Thao D and Becker, Jeffrey H and Argus, Aria A and Baba, Kenkichi and Kinoshita, Takayoshi and Munshi, Hidayatullah G and Scheidt, Karl A},
  title = {Exploiting Acquired Drug Resistance in Pancreatic Cancer through Selective Covalent Targeting of MAP2K4/7},
  journal = {ACS Chemical Biology},
  year = {2026},
  doi = {10.1021/acschembio.6c00580}
}
Kostenlos starten →